Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v15-EN Version v15-EN
Language English English
Date Updated 2024-04-05 2024-04-05
Drug Identification Number 02471477 02471477
Brand name OZEMPIC OZEMPIC
Common or Proper name OZEMPIC 0.25MG/0.5MG OZEMPIC 0.25MG/0.5MG
Company Name NOVO NORDISK CANADA INC NOVO NORDISK CANADA INC
Ingredients SEMAGLUTIDE SEMAGLUTIDE
Strength(s) 1.34MG 1.34MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size 1 1
ATC code A10BJ A10BJ
ATC description
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2023-11-15 2023-11-15
Actual start date
Estimated end date 2024-02-15 2024-02-15
Actual end date 2024-02-16 2024-02-16
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Health Canada expedited the approval of a new 3 mL Ozempic® low dose (0.25mg/0.5mg) pen to stabilize Ozempic® low dose (0.25mg/0.5mg) supply. The shortage of the Ozempic® (0.25mg/0.5mg) pen listed on the Drug Shortages webpage applies only to the previous 1.5mL pen and will be maintained until the transition to the new 3mL pen is complete. Health Canada expedited the approval of a new 3 mL Ozempic® low dose (0.25mg/0.5mg) pen to stabilize Ozempic® low dose (0.25mg/0.5mg) supply. The shortage of the Ozempic® (0.25mg/0.5mg) pen listed on the Drug Shortages webpage applies only to the previous 1.5mL pen and will be maintained until the transition to the new 3mL pen is complete.
Health Canada comments